Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications
Association Between Plasma Phosphorylated Tau-217 and Cognition in Parkinson's Disease.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: November 20, 2025
Bridging the gap: Innovative workforce models to address healthcare shortages.
Journal: Journal of hospital medicine
Published: November 18, 2025
"Where do I go from here?" Navigating a lifelong road without a map: the care experiences of hereditary cancer patients.
Journal: European journal of human genetics : EJHG
Published: September 02, 2025
Bilateral oophorectomy and the probability of amnestic mild cognitive impairment among carriers of a pathogenic variant in BRCA1 or BRCA2.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: March 20, 2025
Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: October 16, 2024
Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma.
Journal: JCO precision oncology
Published: August 05, 2024
Online unsupervised performance-based cognitive testing: A feasible and reliable approach to scalable cognitive phenotyping of Parkinson's patients.
Journal: Parkinsonism & related disorders
Published: June 26, 2024
"Should I Let Them Know I Have This?": Multifaceted Genetic Discrimination and Limited Awareness of Legal Protections among Individuals with Hereditary Cancer Syndromes.
Journal: Public health genomics
Published: May 11, 2024
Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia.
Journal: JTO clinical and research reports
Published: March 27, 2024
Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 27, 2023
Last Updated: 09/26/2026